RPG Life Sciences to Acquire API Business of Raghava Life Sciences for Rs 135 Crore
RPG Life Sciences announced that its wholly owned subsidiary, RPG Active Pharma, will acquire the active pharmaceutical ingredients (API) and intermediates business of Raghava Life Sciences for up to Rs 135 crore. The acquisition, conducted through a slump sale on a going-concern basis, is subject to customary closing conditions and regulatory approvals. This move aims to expand RPG Active Pharma's manufacturing capacity, product portfolio, and regulatory capabilities, leveraging Raghava's WHO-GMP and EU-GMP approved facility near Hyderabad.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (62/100). Lens Score 41/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 3 Sept, 04:55 am. Other outlets followed.